Law360: Economics Of Harm From Biologic-Biosimilar Competition
For more than two decades and despite the Biologics Price Competition and Innovation Act of 2009, the Hatch-Waxman brand-generic disputes have dominated the...
Product development in the life sciences sector is frequently complex, costly, and time-consuming, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our experience helps clients navigate disputes involving drug development and commercialization and identify relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches.
Engagements
- 01CRA addressed a claim that a company had improperly failed to pay required development milestones upon termination of a drug development programIn litigation before the Delaware Court of Chancery, a CRA expert was asked to address the basis for a company’s decision to terminate the development of a...View engagement
- 02AAA arbitration regarding a collaboration and license agreementCRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning the “fair market value” of rights exchanged in later...View engagement
- 03AAA arbitration regarding breach of purchase agreementCRA was retained by the claimant in a dispute at AAA alleging breach of a purchase agreement due to the respondent’s alleged failure to make contracted minimum...View engagement